BackFulcrum Therapeutics Overview
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Target Price

Where could FULC trade next? Consensus target price: $3.6.

Get informed when a big investor buys or sells

+ Follow

Share Price

$3.8

Average Target Price

$3.605.3% downside

5 analysts in the last 4 months

High: $4 | Low: $3

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-06-02H.C. WainwrightAndrew Fein$321.1% downsideOpen
2026-06-02Jefferies$45.3% upsideOpen
2026-06-02Leerink Partners$45.3% upsideOpen
2026-06-02Truist FinancialGregory Renza$45.3% upsideOpen
2026-06-02Piper Sandler$321.1% downsideOpen
2026-02-24Truist FinancialGregory Renza$17347.4% upsideOpen
2025-12-11Truist Financial$18373.7% upsideOpen
2025-12-08Stifel Nicolaus$25557.9% upsideOpen
2025-12-08Cantor FitzgeraldKristen Kluska$24531.6% upsideOpen
2025-12-08RBC Capital$10163.2% upsideOpen
2025-12-08Piper Sandler$23505.3% upsideOpen
2025-12-08H.C. Wainwright$25557.9% upsideOpen
2025-11-24Truist Financial$14268.4% upsideOpen
2025-11-24H.C. WainwrightAndrew Fein$18373.7% upsideOpen
2025-10-30Piper Sandler$16321.1% upsideOpen
2025-10-21Leerink Partners$20426.3% upsideOpen
2025-07-29H.C. Wainwright$12215.8% upsideOpen
2025-05-29Piper SandlerEdward Tenthoff$9136.8% upsideOpen
2025-05-23Leerink PartnersJoseph Schwartz$12215.8% upsideOpen
2024-09-13H.C. WainwrightAndrew Fein$45.3% upsideOpen
2024-09-12RBC CapitalGregory Renza$45.3% upsideOpen
2024-09-12Stifel NicolausDae Gon Ha downgraded Fulcrum Therapeutics$321.1% downsideOpen
2024-09-12Bank of America SecuritiesTazeen Ahmad$247.4% downsideOpen
2024-09-09Bank of America SecuritiesTazeen Ahmad$10163.2% upsideOpen
2024-09-03RBC CapitalGregory Renza$15294.7% upsideOpen
2024-05-20Cantor FitzgeraldKristen Kluska$23505.3% upsideOpen
2024-05-13Goldman SachsCorinne Jenkins$15294.7% upsideOpen
2024-05-13Stifel NicolausDae Gon Ha$22478.9% upsideOpen
2024-03-13RBC CapitalGregory Renza$14268.4% upsideOpen
2022-11-15Goldman Sachs$11189.5% upsideOpen
2022-11-08Piper SandlerEdward Tenthoff$18373.7% upsideOpen

Fulcrum Therapeutics (FULC) FAQ

Fulcrum Therapeutics (FULC) currently reports a target price of $3.6. Use the charts on this page to explore Fulcrum Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Fulcrum Therapeutics is $3.6, about 5.3% downside from the current share price of $3.8. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $3.6, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fulcrum Therapeutics, and consider following FULC for alerts when major investors trade the stock.

Fulcrum Therapeutics is classified in the Healthcare sector. On target price, it currently shows $3.6. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FULC with unrelated industries.